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Introduction: The Japanese Respiratory Society Guidelines for the Management of Commu-
nity-Acquired Pneumonia (CAP) in Adults (JRS 2005) were published to revise the Basic
Concept for the Management of CAP in Adults (JRS 2000). Revisions in JRS 2005 mainly
focused on the criteria for the assessment of pneumonia severity and the differentiation
between bacterial pneumonia and atypical pneumonia. To evaluate the JRS 2005 criteria for
the assessment of pneumonia severity, we conducted a prospective survey.
Subjects and methods: The survey was conducted from July 2006 to March 2007 as a nationwide
joint study by 200 institutions. The study subjects included patients agedZ16 years of age who
had CAP. The severity at initial consultationwas determined using the criteria established by JRS
2005, JRS 2000, and Infectious Diseases Society of America Guidelines (IDSA-GLs). The survival
outcome 30 days after the start of the initial antimicrobial agent treatment was confirmed.
Results: A total of 1875 patients were analyzed. The numbers of cases of pneumonia assessed as
being moderate and severe were significantly lower when the JRS 2005 criteria were used than
when the JRS 2000 criteria were used. Thus, the severity of pneumonia could be determined
more appropriately using the JRS 2005 criteria. Furthermore, the severity-dependent prediction
of fatal outcomes or mortality according to these criteria was similar to that determined using
the IDSA-GLs.anese Respiratory Society. Published by Elsevier B.V. All rights reserved.
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R E S P I R ATO RY I N V E S T I G AT I O N 50 ( 2012 ) 14 –22 15Conclusions: Determining severity on the basis of JRS 2005 can resolve nearly all the problems
encountered with JRS 2000; these criteria were found to be useful and rapidly and easily
applicable in clinical practice.
& 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Treatment of community-acquired pneumonia (CAP) must often
be started empirically after speculating on the identity of the
causative organism. However, actual treatment strategies vary
widely due to the diversity of causative organisms, available
antimicrobial agents, and clinical settings, as well as doctors’
level of expertise. In 2000, the Japanese Respiratory Society (JRS)
published ‘‘Basic Concepts in the Medical Care of CAP in Adults’’
(JRS 2000) [1], which proposed standardized practices for the
treatment of pneumonia in Japan. In 2005, a revised version,
‘‘Guidelines for the Management of CAP in Adults’’ (JRS 2005) [2],
was issued based on the results of a survey aimed at validating
and revising JRS 2000 [3] and on the validation by the Committee
for JRS Guidelines in the Management of Respiratory Infections.
The major changes in this revision were criteria for determining
severity and differentiating between bacterial and atypical
pneumonia. As per JRS 2000, the severity of pneumonia was
determined on the basis of physical findings and test results;
however, body temperature, white blood cell count, C-reactive
protein level, and other parameters used at that timewere found
not to accurately reflect clinical severity [3]. Therefore, a review
was conducted with reference to guidelines used in Western
countries, such as the guidelines of the Infectious Disease Society
of America (IDSA-GLs) [4] and the British Thoracic Society (BTS-
GLs) [5–7]. On the basis of the BTS-GLs, which were believed to be
easier to apply in clinical practice in Japan, JRS 2005 was
established, according to which severity was determined based
on age, blood urea nitrogen (BUN) level or presence of dehydra-
tion, SpO2, impaired consciousness, and blood pressure.
We conducted a nationwide, multicenter joint study of
JRS 2005 to confirm the validity of the new criteria for
determining severity and differentiating between disease
types, and to clarify the status of antimicrobial agent use in
initial treatment. We report here the major results obtained in
our study on the criteria for determining severity.2. Subjects and methods
2.1. Division of roles and responsibilities
The roles of each author were as follows:
Akira Watanabe: Principal investigator
Responsible for reviewing the overall study procedures, plans,
and protocol; evaluating safety information; deciding whether to
adopt problem cases; handling data in cases of deviation from
the protocol; and responding to unexpected events.
Hajime Goto, Shigeru Kohno, and Toshiharu Matsushima:
Coordinating and regional representative investigators
Responsible for reviewing the protocol and managing the
surveillance in each region, deciding whether to adoptproblem cases, handling data in cases of deviation from the
protocol, and responding to unexpected events.
Shosaku Abe, Akira Watanabe, Nobuki Aoki, Kaoru Shimokata,
Keiichi Mikasa, and Yoshihito Niki: Regional representative
investigators
Responsible for operating the surveillance in each region,
deciding whether to adopt problem cases, handling data in
cases of deviation from the protocol, and responding to
unexpected events.
Surveillance office functions, clinical data collection, clin-
ical data management, and statistical analysis were con-
ducted at the following locations:
Surveillance office, clinical data management and statis-
tical analysis: Taisho Pharmaceutical Co., Ltd., and Toyama
Chemical Co., Ltd.
Clinical data collection: Taisho Toyama Pharmaceutical
Co., Ltd.2.2. Participating institutions and survey period
The survey was conducted from July 2006 to March 2007 as a
joint nationwide study by 200 institutions with respiratory
specialists (Table 1). Among patients treated on or after the date
the survey was started, patients who met the inclusion criteria
were consecutively enrolled in the order in which medication
was started until a predetermined number of cases was reached.2.3. Subjects
The study subjects were patients aged Z16 years who had
CAP and presented with clinical symptoms such as cough,
sputum, and fever, and had infiltrative shadows that
appeared suddenly on chest X-ray, chest computed tomogra-
phy, or other imaging modalities. Patients who developed
pneumonia Z48 h after entering the hospital (hospital-
acquired pneumonia) or who improved after pretreatment
with antimicrobial agents were excluded.2.4. Observation and test items
The observation data collected at initial consultation included
patient background, pretreatment with antimicrobial agents
(within 1 week prior to the start of initial antimicrobial agent
treatment), body temperature, pulse rate, sputum, respiratory
rate, and clinical symptoms such as presence or absence of
pleural effusion, as well as chest X-ray and clinical test
findings. The survival outcome (survival or death and cause of
death) 30 days after the start of initial antimicrobial agent
treatment was confirmed. In the survey, place of pneumonia
onset and treatment was classified as home, outpatient
setting, inpatient setting, or nursing home.
Table 1 – Institutions participating in this study.
NTT East Corporation Sapporo Hospital Mitsui Memorial Hospital Kitasato University School of Medicine
Sapporo Hospital of Hokkaido Railway
Company
Toranomon Hospital Sakuramichi Clinic
Sapporo Social Insurance General
Hospital
Tokyo Kouseinenkin Hospital Tokai University Oiso Hospital
Chitose City Hospital Kanto Central Hospital of the Mutual
Aid Association of Public School
Teachers
Maebashi Red Cross Hospital
Obihiro Kosei General Hospital Toho University Ohashi Medical
Center
Fujioka General Hospital
Social Welfare Corporation Hokkaido
Social Work Association OBIHIRO Hospital
Kugayama Hospital Tomioka General Hospital
Hokkaido Chuo Rosai Hospital Tokyo Kyosai Hospital Gunma University Graduate School of Medicine
National Hospital Organization
Asahikawa Medical Center
National Hospital Organization Tokyo
Medical Center
Tone Chuo Hospital
National Hospital Organization Hakodate
National Hospital
Tokyo Rosai Hospital Keiaido Hospital
Hakodate Municipal Hospital Kyorin University School of Medicine National Hospital Organization Ibarakihigashi
National Hospital
Hirosaki Chuo Hospital Machida Municipal Hospital National Hospital Organization Mito Medical Center
Akita City Hospital Showa General Hospital Kofu City Hospital
Yamamoto Kumiai Hospital Municipal Akiru Medical Center Ashikaga Red Cross Hospital
Morioka Red Cross Hospital Kawaguchi Municipal Medical Center Utsunomiya Social Insurance Hospital
Tohoku University Graduate School of
Medicine
Saitama Red Cross Hospital Saiseikai Utsunomiya Hospital
Tohoku Kosei Nenkin Hospital Soka Municipal Hospital Iida Municipal Hospital
Sendai Open Hospital Sendai City Medical
Center
Dokkyo Medical University Koshigaya
Hospital
INA Central Hospital
Japanese Red Cross Sendai Hospital Hanyu General Hospital Matsumoto Kyoritsu Hospital
South Miyagi Medical Center Fukaya Red Cross Hospital Nagano Red Cross Hospital
Tohoku Rosai Hospital Saitama Medical University Hospital Nagano Municipal Hospital
Katta General Hospital Nippon Medical School INBA-HITEC
Medical Center
Shinrakuen Hospital
Yonezawa City Hospital Saisei Hospital Sado General Hospital
Sanyudo Hospital Sannoh Hospital Medical Center Niigata Rinko Hospital
Jusendo General Hospital Juntendo University Urayasu Hospital Tachikawa General Hospital
Kashima Hospital Tokyo Dental College Ichikawa
General Hospital
Nagaoka Chuo General Hospital
Kureha General Hospital Showa University Fujigaoka Hospital Niigata Prefectural Muikamachi Hospital
Higashijyujyo Hospital Showa University Yokohama
Northern Hospital
Niigata Rousai Hospital
Juntendo University Nerima Hospital Seirei Yokohama General Hospital Niigataken Saiseikai Sanjo Hospital
Koto Hospital Yokohama Sakae Kyosai Hospital Niigata Prefectural Kamo Hospital
The Fraternity Memorial Hospital Yokohama City University Medical
Center
Nagaoka Red Cross Hospital
Kyoundo Hospital Sasaki Research
Institute
Kawasaki General Hospital Nagoya University Graduate School of Medicine
Juntendo University Japan Labour Health and Welfare
Organization Kanto Rosai Hospital
Nagoya East Municipal Medical Center
Eiju General Hospital Fujisawa City Hospital National Hospital Organization Nagoya Medical
Center
Tosei General Hospital Osaka Koseinenkin Hospital Tottori Seikyo Hospital
Anjo Kosei Hospital Osaka Kaisei Hospital San-in Rosai Hospital
Toyota Kosei Hospital Aichi Prefectural
Welfare Federation of Agricultural
Cooperatives
Aizenbashi Hospital Kagawa Rosai Hospital
Aichi Prefectural Koseiren Showa Hospital Higashiosaka City General Hospital Takamatsu Red Cross Hospital
Japanese Red Cross Nagoya Daiichi
Hospital
Kinki University Faculty of Medicine Tokushima Prefectural Central Hospital
Daiyukai General Hospital PL General Hospital Tokushima Municipal Hospital
Nagoya Ekisaikai Hospital Kishiwada City Hospital Ehime Prefectural Central Hospital
Mie Prefectural General Medical Center Seichokai Fuchu Hospital Ehime University Graduate School of Medicine
KOMONO Hospital Tenri Hospital Matsuyama Shimin Hospital
Mie University Graduate School of
Medicine
Nara Prefectural Nara Hospital Chikamori Hospital
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Table 1 – (continued)
National Hospital Organization, Mie Chuo
Medical Center
Nara Prefectural Gojo Hospital National Hospital Organization Kochi National
Hospital
Hashima City Hospital Yoshino Municipal Hospital Harasanshin Hospital
Gifu Prefectural General Medical Center Nara Medical University Munakata Suikokai General Hospital
Nishimino Welfare Hospital Naga Municipal Hospital Japan Seamen’s Relief Association Moji Hospital
Ogaki Municipal Hospital National Hospital Organization
Minami Wakayama Medical Center
Independent Administrative Agency Japan Labour
Health and Welfare Organization, Kyushu Rosai
Hospital
Yaizu City Hospital Graduate School of Medicine, Kyoto
University
Yame General Hospital
Numazu City Hospital Kyoto First Red Cross Hospital National Hospital Organization Ureshino Medical
Center
Iwata City Hospital Shiga University of Medical Science Sasebo City General Hospital
Kanazawa Red Cross Hospital Shiga Medical Center for Adults Hokusho Central Hospital
Ishikawa-ken Saiseikai Kanazawa
Hospital
Otsu Red Cross Hospital Nagasaki Rosai Hospital
Kanazawa University Hospital Kobe City Medical Center West
Hospital
Nagasaki Medical Center of Neurology
Kanazawa Social Insurance Hospital Kinki Central Hospital of Mutual Aid
Association of Public School Teachers
Isahaya Health Insurance General Hospital
Kanazawa Medical University Hospital National Hospital Organization Kobe
Medical Center
Omura Municipal Hospital
Ishikawa Prefectural Central Hospital Hyogo Prefectural Kakogawa Medical
Center
Nagasaki University Hospital
Kaga City Hospital National Hospital Organization Himeji
Medical Center
Oita Prefecture Saiseikai Hita Hospital Social
Welfare Organization, Saiseikai Imperial Gift
Foundation Inc.
Komatsu Municipal Hospital Hiroshima Prefectural Hospital Oita University Hospital
National Hospital Organization Isikawa
Hospital
Hiroshima Red Cross Hospital and
Atomic Bomb Survivors Hospital
Oita Prefectural Hospital
Fukui Red Cross Hospital JA Fuchu General Hospital Medical Corporation KEIAI-KAI Oita Nakamura
Hospital
University of Fukui Hospital Kawasaki Medical School Kawasaki
Hospital
Oita Kouseiren Tsurumi Hospital
Fukui Social Insurance Hospital Kurashiki Daiichi Hospital Faculty of Medical and Pharmaceutical Sciences
Kumamoto University
Fukuiken Saiseikai Hospital Kaneda Hospital Japan Labour Health and Welfare Organization
Kumamoto Rosai Hospital
Shinseikai Toyama Hospital Kurashiki Central Hospital University of Miyazaki Hospital
Osaka Red Cross Hospital Simonoseki City Hospital Kagoshima Seikyo Hospital
Nakahama Clinic Tottori Prefectural Central Hospital
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Using the JRS 2005 criteria for determining severity (1, maleZ
70 years, female Z75 years; 2, BUN Z21 mg/dL or dehydra-
tion; 3, SpO2 r90% [PaO2, r60 Torr]; 4, impaired conscious-
ness; 5, systolic blood pressurer90 mmHg), severity at initial
consultation was determined to be mild, moderate, severe,
or very severe. To determine severity according to JRS 2000
and IDSA-GLs, the necessary assessment items in those
guidelines were also observed. IDSA-GLs assessment items
that were not examined were scored as 0 in the calculations,
and separate sums were calculated for patients for whom all
items were examined.
2.6. Standardization of determination
Attempts were made to standardize cases by holding clinical
conferences to discuss whether to adopt problem cases, how
to handle data in cases of deviation from the protocol, and
causes of death in patients who died.2.7. Statistical analysis
The w2 test and Fisher’s exact test were used for comparisons.
Spearman’s rank correlation coefficient was used to confirm
correlations.3. Results
3.1. Patient background
From the 200 institutions, 1941 patients were enrolled and
1923 responses were obtained. At clinical conferences, 330
cases extracted from the collected report were discussed and
standardized by the principal investigator to evaluate causa-
tive organisms and the validity of investigators’ comments,
and to review events not included in the study protocol.
A total of 48 patients were excluded from the analysis,
including 2 patients o16 years of age, 14 patients for whom
chest X-ray was not performed at initial consultation or no
Enrolled subjects
n = 1941
Report form collected
n = 1923
Patients for analysis
n = 1875
Severity analysis set
1875=n5002SRJ1785=n)smeti6(5002SRJ
1861=n0002SRJ1800=n)smeti5(5002SRJ
JRS 2000 (9 items) n = 1785 IDSA (incomplete data items) n = 1875
IDSA (complete data items) n = 334
Outcome analysis set n = 1875
1826
1826
=nS 2005RJ
=nS 2000RJ
Disease type analysis set
Excluded from the analysis
n = 48
Report form not collected
n = 18
Fig. 1 – Analysis sets used in this study.
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diseases. A total of 1875 patients were analyzed (Fig. 1).
Patient backgrounds are shown in Table 2. Approximately
60% of the patients were male, and more than half were Z65
years old. The place of onset for 94.7% of patients was
home; however, approximately 70% of patients received
treatment on an inpatient basis. Underlying disease was
present in 41.0% of the cases, and in 23.7% of these cases, the
underlying disease was moderate or more severe. In most
cases (65.8%), the shadow occupied up to one-third of one
lung on the chest X-ray pH was not examined in 74.0% of the
patients.
3.2. Severity and survival outcome
3.2.1. Severity
Table 3 shows the severity determined using JRS 2005 and JRS
2000. Using JRS 2005, 11.2% of the patients were classified as
having severe or very severe disease, while 36.7% were
classified as having severe or very severe disease on the basis
of JRS 2000. Therefore, the percentage of cases determined to
be severe or very severe with the JRS 2005 criteria was
approximately one-third of the percentage of cases deter-
mined to be severe or very severe with the JRS 2000 criteria.
The correlation coefficient between IDSA-GLs and JRS 2005
was 0.6781, and that between IDSA-GLs and JRS 2000 was
0.5829 (data not shown). Therefore, JRS 2005 had a higher
correlation with IDSA-GLs (Table 4). Additionally, for the 334
patients with different backgrounds who had all IDSA-GLs
assessment items, JRS 2005 had a higher correlation with
IDSA-GLs than JRS 2000 (correlation coefficient ¼ 0.7451 and
0.6025, respectively, data not shown).
3.2.2. Survival outcomes
The outcomes according to severity level determined with JRS
2005 and JRS 2000 are shown in Table 5. A high correlationbetween severity and mortality was seen with JRS 2005.
Although a correlation between severity and mortality was
seen with JRS 2000, mortality in severe cases was low (4.1%).
A high correlation between severity and mortality was also
seen with IDSA-GLs.4. Discussion
We surveyed the status of the revised version of JRS 2000–JRS
2005. A similar survey was undertaken for JRS 2000 immedi-
ately after it was issued. The results of that survey showed
the need for further measures related to severity, differentia-
tion between atypical and bacterial pneumonia, severity of
underlying disease and complications, and adjuvant treat-
ment other than antimicrobial agent treatment [3]. While
revising the severity classification in JRS 2005, guidelines used
in Western countries were investigated. Although IDSA-GLs
appropriately reflects survival outcome, the calculation for
scoring severity is complex andwas considered too difficult to
incorporate into the guidelines in Japan. Therefore, JRS 2005
was revised based on BTS-GLs.
In this study, the differences between JRS 2005 and both
IDSA-GLs and JRS 2000 were also investigated for reference.
The percentage of cases determined to be moderate or
more severe on the basis of JRS 2005 was markedly lower than
those determined to be moderate or more severe on the basis
of JRS 2000. In addition, the severity determined using JRS 2005
had a higher correlation with that determined using IDSA-GLs
than with that determined using JRS 2000. In a comparison of
JRS 2005, JRS 2000, and IDSA-GLs, Gomi et al. [8] reported
similar results and suggested that JRS 2005 improved the
‘‘tendency to judge cases as severe’’ as per JRS 2000 and that
the severity of pneumonia could be determined more appro-
priately with JRS 2005 than with JRS 2000. Haranaga et al. [9]
reported that JRS 2005 might be more likely to underestimate
Table 2 – Subject characteristics.
Item
No. of
patients
(%) Item
No. of
patients
(%)
Number of patients in the
analysis
1875
Number of patients in the
analysis
1875
Sex
Male 1101 (58.7) Pulse rate (per min)
Female 774 (41.3) o100 1152 (61.4)
Pregnant 19 (1.0) 100–129 566 (30.2)
Age (years) Z130 35 (1.9)
Male o70, female o75 1081 (57.7) Not tested 122 (6.5)
Male Z70, female Z75 794 (42.3) Sputum
16–19 58 (3.1) P 468 (25.0)
20–29 128 (6.8) PM 493 (26.3)
30–39 223 (11.9) M 357 (19.0)
40–49 127 (6.8) – (Absent) 533 (28.4)
50–59 171 (9.1) Not tested 24 (1.3)
60–69 293 (15.6) Respiratory rate (per min)
70–79 456 (24.3) o20 697 (37.2)
Z80 418 (22.3) 20–29 608 (32.4)
r65 1023 (54.6) Z30 100 (5.3)
Unknown 1 (0.1) Not tested 470 (25.1)
Place of onset Pleural effusion
Home 1775 (94.7) þ (Present) 171 (9.1)
Hospital 8 (0.4)  (Absent) 1694 (90.3)
Nursing home 92 (4.9) Not tested 10 (0.5)
Place of treatment Extent of chest X-ray shadows
Outpatient 538 (28.7) o1/3 of 1 lung 1234 (65.8)
Inpatient 1334 (71.1) Z1/3, o2/3 of 1 lung 505 (26.9)
Nursing home 2 (0.1) Z2/3 of 1 lung 136 (7.3)
Unknown 1 (0.1) Not tested 0 (0.0)
Underlying disease Peripheral leukocyte count (per lL)
No 1103 (58.8) o4000 43 (2.3)
Yes 769 (41.0) 4000–9999 849 (45.3)
Mild 324 (17.3) 10000–19999 859 (45.8)
Other 445 (23.7) Z20000 108 (5.8)
Unknown 3 (0.2) Not tested 16 (0.9)
Complication CRP (mg/dL)
No 1278 (68.2) o10 1000 (53.3)
Yes 596 (31.8) 10–19 557 (29.7)
Unknown 1 (0.1) Z20 298 (15.9)
Relevant medical history Not tested 20 (1.1)
No 1397 (74.5) pH
Yes 473 (25.2) o7.35 38 (2.0)
Unknown 5 (0.3) Z7.35 450 (24.0)
History of adverse drug reaction or allergy Not tested 1387 (74.0)
Drugs Na (mEq/L)
No 1774 (94.6) o130 65 (3.5)
Yes 71 (3.8) Z130 1572 (83.8)
Unknown 30 (1.6) Not tested 238 (12.7)
Others Blood glucose (mmol/L)
No 1805 (96.3) o13.9 1248 (66.6)
Yes 35 (1.9) Z13.9 46 (2.5)
Unknown 35 (1.9) Not tested 581 (31.0)
Antimicrobial chemotherapy within 1 week before initial treatment
in this study
Ht (%)
No 1480 (78.9) o30 135 (7.2)
Yes 349 (18.6) Z30 1599 (85.3)
Unknown 46 (2.5) Not tested 141 (7.5)
Temperature Dehydration
o37.5 1C 688 (36.7) Yes 427 (22.8)
37.5–38.5 1C 731 (39.0) No 1448 (77.2)
Z38.6 1C 434 (23.1) SpO2 r90% (PaO2r60 Torr)
Not tested 22 (1.2) Yes 434 (23.1)
No 1441 (76.9)
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Table 2 (continued )
Item
No. of
patients
(%) Item
No. of
patients
(%)
Number of patients in the
analysis
1875
Number of patients in the
analysis
1875
Impaired consciousness
Yes 95 (5.1)
No 1780 (94.9)
Systolic blood pressure (mmHg)
r90 39 (2.1)
490 1836 (97.9)
Table 3 – Comparison of pneumonia severity assessed by JRS 2005 and JRS 2000.
(n)
JRS 2000 JRS 2005
Mild Moderate Severe Very severe Total (%)
Mild 573 84 0 0 657 (35.0)
Moderate 231 285 0 0 516 (27.5)
Severe 45 433 164 46 688 (36.7)
Unknowna 8 6 0 0 14 (0.7)
Total 857 808 164 46 1875
(%) (45.7) (43.1) (8.7) (2.5)
a Patients ineligible for severity assessment by JRS 2000.
Table 4 – Comparison of pneumonia severity assessed by JRS 2005 and IDSA-GL.
Comparison of pneumonia severity assessed by JRS 2005 and IDSA-GL in patients (n) with at least 1 data item required for
IDSA-GL classification
IDSA JRS 2005
Severity Score Mild Moderate Severe Very severe Total (%)
Mild I–III r90 854 482 1 1 1338 (71.4)
Moderate IV 91–130 3 310 105 7 425 (22.7)
Severe V 4130 0 16 58 38 112 (6.0)
Total 857 808 164 46 1875
(%) (45.7) (43.1) (11.2)
Spearman’s rank-correlation coefficient: r ¼ 0.6781 between JRS 2005 and IDSA-GL; r ¼ 0.5829 between JRS 2000 and IDSA-GL
Comparison of pneumonia severity assessed by JRS 2005 and IDSA-GL in patients (n) with all data items required for IDSA-GL
classification
IDSA JRS 2005
Severity Score Mild Moderate Severe Very severe Total (%)
Mild I–III r90 70 73 0 1 144 (43.1)
Moderate IV 91–130 0 86 46 3 135 (40.4)
Severe V 4130 0 6 28 21 55 (16.5)
Total 70 165 74 25 334
(%) (21.0) (49.4) (29.6)
Spearman’s rank-correlation coefficient: r ¼ 0.7451 between JRS 2005 and IDSA-GL; r ¼ 0.6025 between JRS 2000 and IDSA-GL
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GLs. Such a tendency was not observed for the 10 L.
pneumophila pneumonia patients in this study. However,because L. pneumophila pneumonia symptoms progress
quickly and may become serious, investigation of a greater
number of patients appears warranted.
Table 5 – Mortality according to pneumonia severity assessed by JRS 2005 and JRS 2000.
JRS 2005 and JRS 2000 (n)
Severity Alive
Dead
Unknown
Mortality (%)
Total
From pneumonia Other than pneumonia From pneumonia Total
JRS 2005
Mild 824 0 0 33 0 0 857
Moderate 770 14 11 13 1.8 3.1 808
Severe 145 11 5 3 6.8 9.9 164
Very severe 37 5 4 0 10.9 19.6 46
Total 1776 30 20 49 1.6 2.7 1875
JRS 2000
Mild 630 0 1 26 0 0.2 657
Moderate 500 2 5 9 0.4 1.4 516
Severe 636 28 14 10 4.1 6.2 688
Unknown 10 0 0 4 0 0 14
Total 1776 30 20 49 1.6 2.7 1875
IDSA-GL (n)
Severity Score Alive
Dead
Unknown
Mortality (%)
Total
From
pneumonia
Other than
pneumonia
From
pneumonia
Total
IDSA (incomplete data itemsa)
Mild I–III r90 1288 5 0 45 0.4 0.4 1338
Moderate IV 91–130 397 13 12 3 3.1 5.9 425
Severe V 4130 91 12 8 1 10.8 18.0 112
Total 1776 30 20 49 1.8 2.7 1875
IDSA (complete data itemsb)
Mild I–III r90 139 0 0 5 0 0 144
Moderate IV 91–130 130 4 0 1 3.0 3.0 135
Severe V 4130 45 7 3 0 12.7 18.2 55
Total 314 11 3 6 3.4 4.3 334
a Patients with at least 1 data item required for IDSA-GL classification.
b Patients with the all data items required for IDSA-GL classification.
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the data obtained in this study, and the results were similar to
the findings of the previous survey of JRS 2000 [3]; therefore,
no bias was apparent in the patient background in this study.
With regard to survival outcome, mortality increased in
proportion to the severity determined using JRS 2005. Mortality
in cases determined to be moderate or more severe was lower
with JRS 2005 than with IDSA-GLs. However, the distribution of
severity using JRS 2005 and survival outcome reflects our
experience in daily clinical practice well, and the use of these
guidelines does not appear to be problematic. In addition, only
5 items are required for severity assessment; therefore, and
assessment with JRS 2005 is relatively easy because it can be
performed by using questionnaires or simple tests.5. Conclusions
Determining severity with JRS 2005 can resolve nearly all the
problems encountered with JRS 2000, and the criteria were
demonstrated to be useful and rapidly and easily applicable to
clinical practice. However, further investigation will beneeded in the future for improving the method used to
determine the severity of L. pneumophila pneumonia, since the
number of cases in this study was insufficient.Conflict of interest
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